Ubs Group Ag Actinium Pharmaceuticals, Inc. Transaction History

Ubs Group Ag

$397 Billion
Q1 2024

A detailed history of Ubs Group Ag transactions in Actinium Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 27,716 shares of ATNM stock, worth $225,885. This represents 0.0% of its overall portfolio holdings.

Number of Shares

27,716

Previous 29,757 6.86%

Holding current value

$225,885

Previous $151,000 43.71%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$5.0 - $9.2 $10,205 - $18,777	-2,041 Reduced 6.86%	27,716 $217,000
Q4 2023 Feb 09, 2024	BUY	$4.02 - $6.08 $70,727 - $106,971	17,594 Added 144.65%	29,757 $151,000
Q3 2023 Nov 09, 2023	BUY	$5.91 - $7.37 $71,883 - $89,641	12,163 New	12,163 $72,000
Q1 2023 May 12, 2023	SELL	$8.51 - $14.26 $4,518 - $7,572	-531 Reduced 16.41%	2,704 $25,000
Q4 2022 Feb 08, 2023	BUY	$9.71 - $12.51 $13,584 - $17,501	1,399 Added 76.2%	3,235 $34,000

Q3 2022 Nov 10, 2022	BUY	$4.81 - $8.48 $8,658 - $15,264	1,800 Added 5000.0%	1,836 $13,000
Q2 2022 Aug 10, 2022	BUY	$4.71 - $7.11 $169 - $255	36 New	36 $0
Q1 2022 May 16, 2022	SELL	$4.57 - $6.4 $228 - $320	-50 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$6.01 - $8.8 $601 - $880	-100 Reduced 66.67%	50 $0
Q3 2021 Nov 15, 2021	SELL	$5.76 - $9.67 $15,511 - $26,041	-2,693 Reduced 94.72%	150 $1,000
Q2 2021 Aug 13, 2021	BUY	$7.01 - $8.63 $18,877 - $23,240	2,693 Added 1795.33%	2,843 $22,000
Q1 2021 May 12, 2021	BUY	$7.62 - $9.79 $1,143 - $1,468	150 New	150 $1,000

Others Institutions Holding ATNM

# of Institutions

Shares Held

6.65M

Call Options Held

369K

Put Options Held

148K

View Full List

About Actinium Pharmaceuticals, Inc.

Ticker ATNM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,184,700
Market Cap $205M
Description
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...

More about ATNM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account